- As consumers have become increasingly health conscious as a fitness-interested segment of society, holistic-oriented wellness products have gained a parallel footing as alternatives to prescription drugs
- The trend is exemplified by the recent explosion of interest in cannabis-based products that don’t have marijuana’s drug qualities but do have muscle pain and spasm relieving properties
- Neutra Corp is preparing to introduce a transdermal pain-relief cream based on a CBD formulation designed to benefit athletes whose workouts induce aches and pains
- The CBD market is expected to top $1 billion in sales by 2022, a result of the growing interest and opportunity surrounding the market
Healthy living solutions research and development company Neutra Corp (OTCQB: NTRR) is preparing for the market release of a new transdermal, hemp-based sports cream designed to provide pain relief for amateur athletes and others involved in activities that require strenuous performance.
The cream rollout is the latest product to market created under Neutra’s subsidiary VIVIS Corp., an emerging retail brand of hemp-based health and nutritional products acquired last month as Neutra’s retail presence. Vivis has a line of products that feature a 99 percent or higher grade of hemp-extracted crystalline CBD, and a second product line in the works will feature an 80 percent or higher grade of full-spectrum CBD extract.
“We’re now seeing the positive payoff of hiring a dedicated sports medicine advisor earlier this year,” CEO Sydney Jim stated in a news release about the sports cream development (http://ibn.fm/iazNa). “Our goal with that hire was to develop hemp-based CBD (cannabidiol) products geared to the expanding sports market. VIVIS’ upcoming transdermal sports cream will appeal to the rapidly growing number of active Americans wanting to improve performance, relieve aches and pains, prevent injuries and lead healthier lifestyles.”
All of Vivis’ CBD products are tested and certified by a third party to ensure their purity.
Neutra began as a company interested in presenting all-natural and organic-based products to market in 2011 to help the human body’s ability to heal and regulate itself. The company has been finding a niche in the CBD-based market this year, contemplating the industry forecasts for a rapidly growing billion dollar revenue stream in the United States alone by 2022 (http://ibn.fm/hzoyi).
“In 2019 we’re really looking at trying to figure out how to participate in the hemp-based CBD market,” Jim said as part of an interview he had recently with NetworkNewsAudio (http://ibn.fm/qQbyX). “Our overall goal is to become a vertically integrated company from cultivation to manufacturing to formulation of products and then to distribution and retail sales.”
The CBD market is a subset of the cannabis industry, which has seen an explosion in interest during recent years that has driven legislative changes and a rebirth of valuation for the plant once common in the country’s agricultural circles before it was banned as a drug product labeled as having no practical use.
Hemp-derived CBD, often equated with medical marijuana, has gained widespread popularity as a home remedy for dealing with muscle pains and spasms. Neutra cites U.S. Department of Labor statistics indicating some 66 million people across the country are playing some sort of sport or exercising on any given day, accompanied by Johns Hopkins University research noting most athletics-caused discomforts can be treated through simple means such as creams and topicals.
For more information, visit the company’s website at www.NeutraInc.com
NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.